ISRCTN88972567进行中（未招募）Unknown

Barrett’s oESophagus Trial 4 (BEST4): A Prospective Cohort trial for the Surveillance of Barrett’s Oesophagus using a capsule sponge test and biomarker panel

Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge0 个研究点目标入组 2,000 人开始时间: 2023年11月23日最近更新: 2024年3月18日

适应症

试验速览

暂无简介。

•Have participated in the BEST4 Screening study where;TFF3 positive on capsule sponge and as part of confirmatory endoscopy at participating secondary care site were diagnosed with NDBO defined as endoscopic evidence of BO at least 2cm (Prague C> = 0 and M> = 2) and intestinal metaplasia with no dysplasia in biopsies taken according to the Seattle protocol.
•1. Be aged > = 18years
•2. Have a known diagnosis of NDBO, defined as endoscopic evidence of BO at least 2 cm (Prague C> = 0 and M> = 2) and intestinal metaplasia with no dysplasia in biopsies taken at the previous endoscopy
•3. Be presenting for routine endoscopic surveillance at a participating secondary care site.

•1. Recorded high grade dysplasia on last endoscopy (note, low grade dysplasia or indefinite for dysplasia previous to last endoscopy is not an exclusion)
•2. Recorded diagnosis of an oro-pharynx, oesophageal or gastro-oesophageal tumour, or symptoms of dysphagia (food sticking)
•3. Received prior endoscopic (photodynamic therapy, endoscopic resection or radiofrequency ablation) or surgical intervention to the oesophagus (note, this does not include previous fundoplication treatment)
•4. Recorded oesophageal varices, cirrhosis of the liver (including compensated Child A cirrhosis)
•5. Unable to follow device anti-coagulation medication guidance
•6. Difficulty in swallowing due to a known cerebrovascular accident or neurological disorder
•7. Known pregnancy
•8. Lack capacity to provide informed consent

发起方

Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge